BG Medicine, Inc.

BGMD

US08861T2069

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 15:36:41 06/12/2023 GMT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2016	BG Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2015	CI
2016	BG Medicine Announces Board Changes	CI

BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013; Provides Earnings Guidance for the Year Ending December 31, 2013

November 06, 2013 at 12:35 pm

BG Medicine, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported total revenues of USD 1.030 million compared to USD 0.641 million a year ago. Loss from operations was USD 3.363 million compared to USD 6.536 million a year ago. Net loss was USD 3.665 million compared to USD 6.814 million a year ago. Basic and diluted loss per share was USD 0.13 compared to USD 0.34 a year ago.

For the nine months, the company reported total revenues of USD 2.924 million compared to USD 1.743 million a year ago. Loss from operations was USD 12.713 million compared to USD 20.123 million a year ago. Net loss was USD 13.914 million compared to USD 20.870 million a year ago. Basic and diluted loss per share was USD 0.52 compared to USD 1.04 a year ago. Net cash flows used in operating activities was USD 12.820 million compared to USD 16.521 million a year ago.

Financial guidance for the year ending December 31, 2013 remains unchanged: revenues are expected to be in the range between USD 3.8 and USD 4.0 million and the operating cash burn for the year is expected to range from USD 15.5 to USD 16.5 million and principal payments for 2013 on term loan to be USD 2.5 million.

Latest news about BG Medicine, Inc.

BG Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2015	31/03/16	CI
BG Medicine Announces Board Changes	04/02/16	CI
BG Medicine Withdraws 510(K) Premarket Notification for Proposed Additional Indication for the Bgm Galectin-3® Test	23/12/15	CI
BG Medicine, Inc. Amends License and Distribution Agreement for Galectin-3 with Abbott Laboratories	30/11/15	CI
BG Medicine, Inc. Announces Board Changes	20/11/15	CI
Transcript : BG Medicine, Inc. - Special Call	17/11/15
BG Medicine, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	17/11/15	CI
Certain Options of BG Medicine, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2015.	10/11/15	CI
Certain Warrants of BG Medicine, Inc. are subject to a Lock-Up Agreement Ending on 11-NOV-2015.	10/11/15	CI
Certain shares of BG Medicine, Inc.'s Common Stock are subject to a Lock-Up Agreement Ending on 11-NOV-2015.	10/11/15	CI
Timothy Harris Resigns to Board of Directors and Audit Committee of BG Medicine, Inc	25/09/15	CI
BG Medicine, Inc.(OTCPK:BGMD) dropped from MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	17/09/15	CI
BG Medicine, Inc.(OTCPK:BGMD) dropped from S&P TMI Index	17/09/15	CI
BG Medicine, Inc.(OTCPK:BGMD) dropped from CRSP US Total Market Index	16/09/15	CI
BG Medicine, Inc.(NasdaqCM:BGMD) dropped from NASDAQ Composite Index	15/09/15	CI
Transcript : BG Medicine, Inc., Q2 2015 Earnings Call, Aug 19, 2015	19/08/15
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015	14/08/15	CI
BG Medicine, Inc. Announces Payoff of Secured Term Loan	15/07/15	CI
BG Medicine, Inc. announced that it has received $2.5 million in funding from Flagship Ventures.	13/07/15	CI
BG Medicine, Inc. Announces First Automated Test for Galectin-3 Now Available in U.S	06/07/15	CI
BGMD Seeks Acquisitions	19/05/15	CI
Transcript : BG Medicine, Inc., Q1 2015 Earnings Call, May 14, 2015	14/05/15
BG Medicine, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Financial Guidance for 2015	14/05/15	CI
BG Medicine, Inc. Announces Board Changes	12/05/15	CI
BG Medicine, Inc. announced that it expects to receive $2.5 million in funding from Flagship Ventures.	11/05/15	CI

Chart BG Medicine, Inc.

Duration

Period

More charts

Company Profile

BG Medicine, Inc. (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company's BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation. The automated galectin-3 tests are being developed and commercialized by its diagnostic instrument manufacturing partners and will be performed on its partners' automated platforms. The Company's CardioSCORE test is a multi-analyte biomarker-based blood test that was designed as an aid in the assessment of near-term risk for atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Sector

Pharmaceuticals

More about the company